ALBIO Fundamental Analysis - BIOSYNEX

Fundamental Rating

ALBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 62 industry peers in the Health Care Equipment & Supplies industry. ALBIO has a bad profitability rating. Also its financial health evaluation is rather negative. ALBIO has a valuation in line with the averages, but on the other hand it scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALBIO has reported negative net income.

ALBIO had a negative operating cash flow in the past year.

In multiple years ALBIO reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALBIO reported negative operating cash flow in multiple years.

1.2 Ratios

With a Return On Assets value of -47.65%, ALBIO is not doing good in the industry: 86.15% of the companies in the same industry are doing better.

ALBIO has a worse Return On Equity (-161.36%) than 86.15% of its industry peers.

		Industry Rank	Sector Rank
ROA	-47.65%
ROE	-161.36%
ROIC	N/A

ROA(3y)-10.45%

ROA(5y)6.45%

ROE(3y)-24.44%

ROE(5y)7.2%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 58.82%, ALBIO is in line with its industry, outperforming 53.85% of the companies in the same industry.

In the last couple of years the Gross Margin of ALBIO has remained more or less at the same level.

ALBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	58.82%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.7%

GM growth 5Y-0.09%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALBIO has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALBIO has more shares outstanding

ALBIO has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.74, we must say that ALBIO is in the distress zone and has some risk of bankruptcy.

ALBIO has a Altman-Z score of -0.74. This is in the lower half of the industry: ALBIO underperforms 78.46% of its industry peers.

A Debt/Equity ratio of 0.32 indicates that ALBIO is not too dependend on debt financing.

ALBIO has a Debt to Equity ratio of 0.32. This is comparable to the rest of the industry: ALBIO outperforms 58.46% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Altman-Z	-0.74

ROIC/WACCN/A

WACC5.35%

2.3 Liquidity

ALBIO has a Current Ratio of 0.78. This is a bad value and indicates that ALBIO is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.78, ALBIO is not doing good in the industry: 87.69% of the companies in the same industry are doing better.

A Quick Ratio of 0.46 indicates that ALBIO may have some problems paying its short term obligations.

The Quick ratio of ALBIO (0.46) is worse than 87.69% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.78
Quick Ratio	0.46

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALBIO have decreased strongly by -42.10% in the last year.

The Revenue has decreased by -5.84% in the past year.

ALBIO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.22% yearly.

EPS 1Y (TTM)-42.1%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-60.87%

Revenue 1Y (TTM)-5.84%

Revenue growth 3Y-35.81%

Revenue growth 5Y24.22%

Sales Q2Q%-5.91%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y475%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year15.05%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

ALBIO is valuated cheaply with a Price/Forward Earnings ratio of 1.25.

Compared to the rest of the industry, the Price/Forward Earnings ratio of ALBIO indicates a rather cheap valuation: ALBIO is cheaper than 98.46% of the companies listed in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 23.46, ALBIO is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	1.25

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALBIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALBIO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOSYNEX

EPA:ALBIO (12/24/2025, 7:00:00 PM)

0.59

0 (-0.67%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)07-17 2025-07-17

Earnings (Next)N/A N/A

Inst Owners0.39%

Inst Owner ChangeN/A

Ins Owners5.7%

Ins Owner ChangeN/A

Market Cap11.06M

Revenue(TTM)97.95M

Net Income(TTM)-71.00M

Analysts86.67

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	1.25
P/S	0.11
P/FCF	N/A
P/OCF	N/A
P/B	0.25
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-4.28

EYN/A

EPS(NY)0.47

Fwd EY80.31%

FCF(TTM)-0.56

FCFYN/A

OCF(TTM)-0.32

OCFYN/A

SpS5.22

BVpS2.35

TBVpS-1.49

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-47.65%
ROE	-161.36%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	58.82%
FCFM	N/A

ROA(3y)-10.45%

ROA(5y)6.45%

ROE(3y)-24.44%

ROE(5y)7.2%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.7%

GM growth 5Y-0.09%

F-Score3

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	7.39%
Cap/Sales	4.44%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.78
Quick Ratio	0.46
Altman-Z	-0.74

F-Score3

WACC5.35%

ROIC/WACCN/A

Cap/Depr(3y)147.54%

Cap/Depr(5y)303.81%

Cap/Sales(3y)21.04%

Cap/Sales(5y)14.8%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-42.1%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-60.87%

EPS Next Y475%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-5.84%

Revenue growth 3Y-35.81%

Revenue growth 5Y24.22%

Sales Q2Q%-5.91%

Revenue Next Year15.05%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-72.88%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year2216.67%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y80.7%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y45.32%

OCF growth 3YN/A

OCF growth 5YN/A

BIOSYNEX / ALBIO.PA FAQ

What is the fundamental rating for ALBIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA.

What is the valuation status for ALBIO stock?

ChartMill assigns a valuation rating of 4 / 10 to BIOSYNEX (ALBIO.PA). This can be considered as Fairly Valued.

Can you provide the profitability details for BIOSYNEX?

BIOSYNEX (ALBIO.PA) has a profitability rating of 1 / 10.

What is the earnings growth outlook for BIOSYNEX?

The Earnings per Share (EPS) of BIOSYNEX (ALBIO.PA) is expected to grow by 475% in the next year.

BIOSYNEX (ALBIO.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BIOSYNEX / ALBIO.PA FAQ

What is the fundamental rating for ALBIO stock?

What is the valuation status for ALBIO stock?

Can you provide the profitability details for BIOSYNEX?

What is the earnings growth outlook for BIOSYNEX?